KalVista wins grant for DME treatment

Article

KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.

Related Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
© 2024 MJH Life Sciences

All rights reserved.